CN111902398B - Urat-1抑制剂的盐型 - Google Patents

Urat-1抑制剂的盐型 Download PDF

Info

Publication number
CN111902398B
CN111902398B CN201980021427.0A CN201980021427A CN111902398B CN 111902398 B CN111902398 B CN 111902398B CN 201980021427 A CN201980021427 A CN 201980021427A CN 111902398 B CN111902398 B CN 111902398B
Authority
CN
China
Prior art keywords
compound
pharmaceutical composition
degrees
crystalline form
substantially pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980021427.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111902398A (zh
Inventor
代星
江岳恒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yifang Biotechnology Shanghai Co ltd
Original Assignee
Yifang Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yifang Biotechnology Shanghai Co ltd filed Critical Yifang Biotechnology Shanghai Co ltd
Publication of CN111902398A publication Critical patent/CN111902398A/zh
Application granted granted Critical
Publication of CN111902398B publication Critical patent/CN111902398B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CN201980021427.0A 2018-03-28 2019-03-26 Urat-1抑制剂的盐型 Active CN111902398B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/080889 2018-03-28
PCT/CN2018/080889 WO2019183835A1 (en) 2018-03-28 2018-03-28 Novel salt forms of urat-1 inhibitors
PCT/CN2019/079619 WO2019184897A1 (en) 2018-03-28 2019-03-26 Novel salt forms of urat-1 inhibitors

Publications (2)

Publication Number Publication Date
CN111902398A CN111902398A (zh) 2020-11-06
CN111902398B true CN111902398B (zh) 2024-01-26

Family

ID=68059457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980021427.0A Active CN111902398B (zh) 2018-03-28 2019-03-26 Urat-1抑制剂的盐型

Country Status (10)

Country Link
US (2) US11339127B2 (https=)
EP (1) EP3774733B1 (https=)
JP (1) JP7357634B2 (https=)
KR (1) KR102907394B1 (https=)
CN (1) CN111902398B (https=)
AU (1) AU2019241202B2 (https=)
CA (1) CA3094292A1 (https=)
IL (1) IL277578A (https=)
TW (1) TWI818001B (https=)
WO (2) WO2019183835A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234060B (zh) * 2021-04-30 2022-11-08 山东大学 一种稠杂环吡啶巯乙酸类衍生物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159840A2 (en) * 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Phenylthioacetate compounds, compositions and methods of use
WO2011159839A2 (en) * 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Thioacetate compounds, compositions and methods of use
WO2016023460A1 (zh) * 2014-08-13 2016-02-18 上海页岩科技有限公司 羧酸化合物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8549908B2 (en) * 2010-06-17 2013-10-08 Los Robles Advertising, Inc. Thermal anemometer flow meter for the measurement of wet gas flow

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159840A2 (en) * 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Phenylthioacetate compounds, compositions and methods of use
WO2011159839A2 (en) * 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Thioacetate compounds, compositions and methods of use
WO2016023460A1 (zh) * 2014-08-13 2016-02-18 上海页岩科技有限公司 羧酸化合物及其制备方法和用途

Also Published As

Publication number Publication date
AU2019241202B2 (en) 2024-06-13
WO2019184897A1 (en) 2019-10-03
WO2019183835A1 (en) 2019-10-03
KR20200138260A (ko) 2020-12-09
JP2021519313A (ja) 2021-08-10
AU2019241202A1 (en) 2020-10-01
EP3774733A4 (en) 2021-12-01
EP3774733B1 (en) 2025-09-24
KR102907394B1 (ko) 2025-12-31
EP3774733A1 (en) 2021-02-17
CN111902398A (zh) 2020-11-06
US11685720B2 (en) 2023-06-27
US11339127B2 (en) 2022-05-24
CA3094292A1 (en) 2019-10-03
US20220371996A1 (en) 2022-11-24
IL277578A (en) 2020-11-30
US20210032204A1 (en) 2021-02-04
EP3774733C0 (en) 2025-09-24
TWI818001B (zh) 2023-10-11
JP7357634B2 (ja) 2023-10-06
TW202003467A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
CA3129949C (en) Solid forms of fxr agonists
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
AU2013201519C1 (en) Salts of an epidermal growth factor receptor kinase inhibitor
US12018025B2 (en) Integrin inhibitor and uses thereof
CN111777595A (zh) 一种环己烷甲酰胺类化合物的新晶型及其制备方法
CN111902398B (zh) Urat-1抑制剂的盐型
US10633376B2 (en) Crystalline forms of JAK1-selective inhibitor, processes for preparation and use thereof
RS60749B1 (sr) Natrijumova so inhibitora transportera mokraćne kiseline i njen kristalni oblik
EP2994456A1 (en) Salts of an epidermal growth factor receptor kinase inhibitor
WO2014013465A2 (en) Salts and hydrates of antipsychotics
US11066401B2 (en) Pyrimidine compound, chloride salt thereof, and manufacturing and application of same
WO2016155631A1 (zh) 托吡司他的新晶型及其制备方法
WO2023221078A1 (en) Solid forms of a compound for treating or preventing hyperuricemia or gout
TW202606689A (zh) 一種嘧啶類衍生物的固體形式及其製備方法和應用
CN116056709A (zh) 哒嗪酮化合物
CN115003653A (zh) 艾拉菲诺的多晶型物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 201203 building 63, Lane 1000, zhangheng Road, Pudong New Area, Shanghai

Applicant after: Yifang Biotechnology (Shanghai) Co.,Ltd.

Address before: No. 63, Lane 1000, zhangheng Road, Pudong New Area, Shanghai, 201203

Applicant before: Yifang Biotechnology (Shanghai) Co.,Ltd.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant